CN103720701A - 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 - Google Patents

在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 Download PDF

Info

Publication number
CN103720701A
CN103720701A CN201310524590.3A CN201310524590A CN103720701A CN 103720701 A CN103720701 A CN 103720701A CN 201310524590 A CN201310524590 A CN 201310524590A CN 103720701 A CN103720701 A CN 103720701A
Authority
CN
China
Prior art keywords
sns
dosage
treatment
gemcitabine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201310524590.3A
Other languages
English (en)
Chinese (zh)
Inventor
杰弗里·A·西佛曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103720701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of CN103720701A publication Critical patent/CN103720701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201310524590.3A 2007-10-22 2008-10-21 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 Pending CN103720701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98176607P 2007-10-22 2007-10-22
US60/981,766 2007-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008801223989A Division CN101909613A (zh) 2007-10-22 2008-10-21 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法

Publications (1)

Publication Number Publication Date
CN103720701A true CN103720701A (zh) 2014-04-16

Family

ID=40210512

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310524590.3A Pending CN103720701A (zh) 2007-10-22 2008-10-21 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
CN2008801223989A Pending CN101909613A (zh) 2007-10-22 2008-10-21 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008801223989A Pending CN101909613A (zh) 2007-10-22 2008-10-21 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法

Country Status (8)

Country Link
US (3) US8518872B2 (enExample)
EP (2) EP2214662B1 (enExample)
JP (3) JP6029808B2 (enExample)
CN (2) CN103720701A (enExample)
AU (1) AU2008317400B2 (enExample)
CA (1) CA2703044C (enExample)
MX (1) MX2010004350A (enExample)
WO (1) WO2009054935A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089757A1 (en) 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2025033367A1 (ja) * 2023-08-04 2025-02-13 湧永製薬株式会社 抗腫瘍剤併用療法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS6233176A (ja) 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CN1053668C (zh) 1994-06-14 2000-06-21 大日本制药株式会社 新型化合物及其制法和抗肿瘤剂
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
US6670144B1 (en) 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
CA2363621A1 (en) 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2877202A (en) 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
JP4178783B2 (ja) 2001-10-19 2008-11-12 三菱化学株式会社 光学記録媒体
CA2502979A1 (en) * 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
EP1660473A2 (en) 2003-03-24 2006-05-31 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
WO2005089757A1 (en) 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
CA2566900C (en) 2004-05-21 2014-07-29 Cablesedge Software Inc. Remote access system and method and intelligent agent therefor
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2654876A1 (en) 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. 1-8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
PL2049109T3 (pl) 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
KR20170090535A (ko) 2008-12-31 2017-08-07 선에시스 파마슈티컬스 인코포레이티드 (＋)-1,4-다이하이드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리딘일］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
JP5936862B2 (ja) 2009-02-27 2016-06-22 サネシス ファーマシューティカルズ， インコーポレイテッド Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIROKI SAKAMOTO 等: "Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial", 《JOURNAL OF GASTROENTEROLOGY》 *
JASMIN WRIGHT 等: "SNS-595 Has Synergistic Activity In Vitro With DNA Damaging Agents And Antimetabolites", 《PROCEEDINGS FOR CANCER RESEARCH》 *

Also Published As

Publication number Publication date
JP6029808B2 (ja) 2016-11-24
AU2008317400A1 (en) 2009-04-30
CN101909613A (zh) 2010-12-08
US20160317510A1 (en) 2016-11-03
JP2015057397A (ja) 2015-03-26
MX2010004350A (es) 2010-05-19
EP2214662A1 (en) 2010-08-11
EP2214662B1 (en) 2016-07-13
WO2009054935A1 (en) 2009-04-30
US20140205679A1 (en) 2014-07-24
US8518872B2 (en) 2013-08-27
AU2008317400B2 (en) 2014-10-02
JP2011500805A (ja) 2011-01-06
JP2017031197A (ja) 2017-02-09
EP3141250A1 (en) 2017-03-15
CA2703044C (en) 2016-05-10
CA2703044A1 (en) 2009-04-30
US20100297142A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
CN103720701A (zh) 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
CN103083316B (zh) Sns-595及其使用方法
RU2013110491A (ru) Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
ES2330324T3 (es) Derivados del epotilon para el tratamiento del hepatoma y de otros canceres.
JP2005503323A5 (enExample)
RU2003126170A (ru) Способы введения аналогов эпотилона при лечения рака
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
CN106822099A (zh) 维生素c与苯磺酰胺化合物协同作用的注射用药物组合物
JP2020537689A (ja) Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
CN102309491B (zh) 一种替加氟、吉美斯特复方注射液
AU2016210659A1 (en) METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
WO2021185234A1 (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
KR100869759B1 (ko) 변비형 ｉｂｓ 예방제/치료제
TW202038956A (zh) 用於治療癌症之口服愛萊諾迪肯（ｉｒｉｎｏｔｅｃａｎ）與Ｐ－ｇｐ抑制劑的醫療組合
JP6937065B1 (ja) 間質性肺炎の治療剤
CN112535686B (zh) 激酶抑制剂的新用途
AU2014277779A1 (en) METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
Nakanishi et al. Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors
CN117243947A (zh) 瑞香素及包含其的组合在制备糖尿病并发症药物中的应用
WO2001049299A2 (en) Prevention of ironotecan induced diarrhea with activated carbon
WO2020160813A1 (en) Method of treatment and pharmaceutical dosage form
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
US20140302022A1 (en) 2-carboxamide clycloamino urea derivatives for use in treating vegf-dependent diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20140416

RJ01 Rejection of invention patent application after publication